Short Interest in PharmaCyte Biotech, Inc. (NASDAQ:PMCB) Decreases By 15.9%

PharmaCyte Biotech, Inc. (NASDAQ:PMCB) was the target of a large decrease in short interest in the month of November. As of November 15th, there was short interest totalling 51,900 shares, a decrease of 15.9% from the October 31st total of 61,700 shares. Based on an average daily volume of 34,700 shares, the days-to-cover ratio is presently 1.5 days. Currently, 0.7% of the company’s shares are sold short.

PharmaCyte Biotech Stock Performance

Shares of PMCB opened at $1.71 on Friday. The company’s 50-day moving average price is $1.77 and its 200 day moving average price is $1.89. PharmaCyte Biotech has a 12-month low of $1.39 and a 12-month high of $2.58. The firm has a market cap of $13.13 million, a P/E ratio of 2.59 and a beta of -0.20.

PharmaCyte Biotech (NASDAQ:PMCB) last released its quarterly earnings results on Monday, September 16th. The company reported $0.14 earnings per share (EPS) for the quarter.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.